[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Hosokawa Y, Saiki S, Hanafusa T, Meguro N, Maeda O, Kinouchi T, Kuroda M, Usami M, Kotake T: [A case of adult Wilms' tumor]. Hinyokika Kiyo; 2001 Sep;47(9):641-3
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adult Wilms' tumor].
  • Wilms' tumor is very rarely found in adults and there are no established treatment guidelines for such tumors in adults.
  • Computed tomography scan revealed a large right renal mass with enlarged lymph nodes.
  • Angiography showed a hypovascular tumor.
  • She underwent right nephrectomy and resection of lymph node metastasis with a diagnosis of malignant renal tumor.
  • The disease was classified as stage III according to the National Wilms' Tumor Study classification.
  • The patient received adjuvant chemotherapy consisting of ifosfamide, cisplatin, and etoposide.
  • This protocol was selected because of the published poor results with the standard Wilms' tumor chemotherapeutic agents when used in adults.
  • She remained without tumor recurrence as of six months after surgery.
  • Development of better therapeutic approaches to adult Wilms' tumor is awaited.
  • [MeSH-major] Kidney Neoplasms / therapy. Wilms Tumor / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Nephrectomy. Treatment Outcome

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11692602.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 12
  •  go-up   go-down


2. Milosevic DP, Kreacic M, Despotovic N, Erceg P, Milanovic P, Mihajlovic G, Mitic S, Davidovic M: The principles of chemotherapy of colorectal cancer in elderly. Adv Gerontol; 2007;20(4):75-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The principles of chemotherapy of colorectal cancer in elderly.
  • The prevalence of colorectal cancer (CRC) increases significantly with age, with 40% of patients in Europe being older than 74 years of age at the time of initial diagnosis.
  • The individualized management of the older-aged patient with cancer is based on the answers to the following questions:.
  • 1) will the patient die of cancer or with cancer;.
  • 2) will the patient suffer cancer-related morbidity; and 3) is the patient able to handle the toxicity of treatment?
  • More than chronological age, the following parameters are important when elderly patients are to be treated with antineoplastic agents: general condition, liver function, kidney function and bone marrow status.
  • Frail elderly with malignant disease should not be treated with cytostatic therapy.
  • In the case of fit elderly, the standard chemotherapy (i.e.
  • In elderly ineligible for combination chemotherapy, the capecitabine used orally, as a single-agent therapy, is an important therapeutic option for colorectal cancer.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18383715.001).
  • [ISSN] 1561-9125
  • [Journal-full-title] Advances in gerontology = Uspekhi gerontologii
  • [ISO-abbreviation] Adv Gerontol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. Batchelor DJ, Bright SR, Ibarrola P, Tzannes S, Blackwood L: Long-term survival after combination chemotherapy for bilateral renal malignant lymphoma in a dog. N Z Vet J; 2006 Jun;54(3):147-50
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after combination chemotherapy for bilateral renal malignant lymphoma in a dog.
  • CLINICAL FINDINGS AND DIAGNOSIS: Radiography and ultrasonography revealed bilateral renomegaly, and cytology of fine needle aspirates from the kidneys was diagnostic of malignant lymphoma.
  • The dog was treated with a modified high-dose cyclophosphamide-, vincristine-, and prednisolone-based chemotherapy protocol, achieved remission, and returned to normal quality of life.
  • Survival time was 346 days from the time of diagnosis.
  • CLINICAL RELEVANCE: Malignant lymphoma in the kidneys of dogs has been considered to carry a uniformly poor prognosis.
  • Long-term remission after medical treatment has not previously been reported.
  • The favourable outcome in this case illustrates the limitations of clinical staging in determining the outcome for individual patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dog Diseases / drug therapy. Kidney Neoplasms / drug therapy. Lymphoma / drug therapy
  • [MeSH-minor] Animals. Dogs. Male. Neoplasm Staging. Prognosis. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16751846.001).
  • [ISSN] 0048-0169
  • [Journal-full-title] New Zealand veterinary journal
  • [ISO-abbreviation] N Z Vet J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  •  go-up   go-down


Advertisement
4. Li Q, Feng FY, Chen Q, Jiao SC, Li F, Wang HQ, Huang WX, Ling CQ, Li MZ, Ren J, Zhang Y, Qin FZ, Zhou MZ, Zhu RZ: [Multicenter phase II clinical trial of uroacitides injection in the treatment for advanced malignant tumors]. Zhonghua Zhong Liu Za Zhi; 2008 Jul;30(7):534-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multicenter phase II clinical trial of uroacitides injection in the treatment for advanced malignant tumors].
  • OBJECTIVE: To investigate the efficacy, safety and the life quality improvement of uroacitides injection in the treatment for patients with advanced malignant tumors.
  • METHODS: A total of 160 patients with advanced stage cancers were enrolled into this multicenter, open and non-randomized phase II clinical trial, including cancers of the lung (33 cases), liver (45 cases), breast (17 cases), esophagus (11 cases), stomach (18 cases), colon (19 cases), pancreas (3 cases) and kidney (4 cases), and glioma (10 cases).
  • The total objective response rate (ORR, CR + PR)) and tumor control rate (CR + PR + MR + SD) of the 138 evaluable patients were 5.8% and 65.2%, respectively.
  • [MeSH-major] Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Methyltransferases / therapeutic use. Peptides / therapeutic use. Phenylacetates / therapeutic use
  • [MeSH-minor] Breast Neoplasms / blood. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Catheterization, Central Venous. Colorectal Neoplasms / blood. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Humans. Nausea / chemically induced. Neoplasm Staging. Quality of Life. Remission Induction. Salvage Therapy. Treatment Outcome. Vomiting / chemically induced. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062723.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Peptides; 0 / Phenylacetates; 0 / alpha-Fetoproteins; 0 / cell differentiation agent II; EC 2.1.1.- / Methyltransferases
  •  go-up   go-down


5. Camassei FD, Arancia G, Cianfriglia M, Bosman C, Francalanci P, Ravà L, Jenkner A, Donfrancesco A, Boldrini R: Nephroblastoma: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells. Am J Clin Pathol; 2002 Mar;117(3):484-90
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephroblastoma: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells.
  • The development of chemoresistance in a variety of cancers seems related to overexpression of the P-glycoprotein (P-gp) drug pump.
  • Nephroblastoma, the most common malignant renal tumor of childhood, usually is responsive to treatment, and prognosis is favorable in most cases.
  • However, the disease in a subset of patients is refractory to treatment, and the disease follows an aggressive course.
  • To study P-gp expression in this tumor and its correlation with outcome, tumor samples from 93 patients were examined by immunohistochemical analysis.
  • P-gp expression was determined separately in both tumor cells and intratumoral capillary endothelium.
  • The likelihood ratio test, the Kaplan-Meier method, and the log-rank test were used to evaluate its association with clinical course, grade, stage, and administration of preoperative chemotherapy.
  • While no association of P-gp expression in tumor cells with clinical course, stage, and grade could be demonstrated, positivity in endothelial cells correlated significantly with unfavorable outcome, suggesting that chemoresistance depended on an active blood-tumor barrier.
  • Previous chemotherapy induced P-gp overexpression in tumor cells.
  • [MeSH-major] Kidney Neoplasms / chemistry. Kidney Neoplasms / pathology. P-Glycoprotein / analysis. Wilms Tumor / chemistry. Wilms Tumor / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capillaries. Child. Child, Preschool. Combined Modality Therapy. Dactinomycin / therapeutic use. Endothelium, Vascular / chemistry. Female. Humans. Immunohistochemistry. Infant. Male. Neoplasm Staging. Postoperative Care. Preoperative Care. Radiotherapy. Remission Induction. Retrospective Studies. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11888090.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / P-Glycoprotein; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; SIOP protocol
  •  go-up   go-down


6. Tröbs RB, Hänsel M, Friedrich T, Bennek J: A 23-year experience with malignant renal tumors in infancy and childhood. Eur J Pediatr Surg; 2001 Apr;11(2):92-8
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 23-year experience with malignant renal tumors in infancy and childhood.
  • A retrospective analysis of 77 children treated between 1974 and 1996 was undertaken to evaluate morbidity and the evolution of therapy.
  • A Wilms' tumor (WT) was present in 73 children.
  • High-risk WT were diagnosed in 12 of 63 patients (19%) (NB with anaplasia 10, clear cell sarcoma 1, malignant rhabdoid tumor 1).
  • We observed 3 children of school age with renal carcinoma and one patient with an intrarenal neuroblastoma.
  • According to the SIOP/GPOH protocol in 1989, the regimen was switched from primary surgery to preoperative chemotherapy without biopsy in 1989 (11 pats.).
  • In 3 patients preoperative diagnosis by means of imaging failed.
  • During preoperative chemotherapy a venous occlusive disease of the liver occurred in 2 patients.
  • Preoperative chemotherapy led to an impressive tumor shrinkage in the majority of patients.
  • In our experience, reduction of tumor volume due to preoperative chemotherapy facilitates tumor removal by surgery and may prevent tumor spillage and the deleterious effects of radiation in young children.
  • Surgery without delay is necessary if the diagnosis is unclear or the tumor fails to respond to preoperative chemotherapy.
  • [MeSH-major] Kidney Neoplasms / surgery. Wilms Tumor / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11371043.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Kaste SC, Dome JS, Babyn PS, Graf NM, Grundy P, Godzinski J, Levitt GA, Jenkinson H: Wilms tumour: prognostic factors, staging, therapy and late effects. Pediatr Radiol; 2008 Jan;38(1):2-17
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms tumour: prognostic factors, staging, therapy and late effects.
  • Wilms tumour is the most common malignant renal tumour in children.
  • Dramatic improvements in survival have occurred as the result of advances in anaesthetic and surgical management, irradiation and chemotherapy.
  • Current therapies are based on trials and studies primarily conducted by large multi-institutional cooperatives including the Société Internationale d'Oncologie Pédiatrique (SIOP) and the Children's Oncology Group (COG).
  • The primary goals are to treat patients according to well-defined risk groups in order to achieve the highest cure rates, to decrease the frequency and intensity of acute and late toxicity and to minimize the cost of therapy.
  • The SIOP trials and studies largely focus on the issue of preoperative therapy, whereas the COG trials and studies start with primary surgery.
  • This paper reviews prognostic factors and staging systems for Wilms tumour and its current treatment with surgery and chemotherapy.
  • Surgery remains a crucial part of treatment for nephroblastoma, providing local primary tumour control and adequate staging and possibly controlling the metastatic spread and central vascular extension of the disease.
  • The late effects for Wilms tumour and its treatment are also reviewed.
  • The treatment of Wilms tumour has been a success story, and currently in excess of 80% of children diagnosed with Wilms tumour can look forward to long-term survival, with less than 20% experiencing serious morbidity at 20 years from diagnosis.
  • The late complications are a consequence of the type and intensity of treatment required, which in turn reflects the nature and extent of the original tumour.
  • Continual international trial development and participation will improve matching of treatment needs with prognosis, reducing long-term complications in the majority.
  • [MeSH-major] Kidney Neoplasms / pathology. Kidney Neoplasms / therapy. Wilms Tumor / pathology. Wilms Tumor / therapy
  • [MeSH-minor] Child. Clinical Trials as Topic. Combined Modality Therapy. Humans. Male. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Risk Factors. Survival Analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Radiol. 2008 Apr;38(4):483; author reply 484-5 [18299824.001]
  • [CommentIn] Pediatr Radiol. 2008 Jan;38(1):1 [18026722.001]
  • [Cites] J Clin Oncol. 1983 Oct;1(10):604-9 [6321673.001]
  • [Cites] J Pediatr Surg. 2006 Apr;41(4):652-7; discussion 652-7 [16567171.001]
  • [Cites] Med Pediatr Oncol. 2002 Apr;38(4):258-9 [11920790.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1546-56 [7602343.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):393-8 [11159177.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4301-7 [10485476.001]
  • [Cites] N Engl J Med. 1987 Sep 3;317(10):588-93 [3475572.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):488-500 [11208843.001]
  • [Cites] J Natl Cancer Inst. 1997 Aug 6;89(15):1089-91 [9262241.001]
  • [Cites] Int J Cancer. 1989 Mar 15;43(3):399-402 [2538400.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Mar-Apr;24(3):192-8 [11990305.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1997;9(6):381-4 [9448966.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):887-91 [8756386.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 2):1519-21; discussion 1521 [16148643.001]
  • [Cites] Nat Rev Cancer. 2005 Sep;5(9):699-712 [16110318.001]
  • [Cites] Eur J Cancer. 2006 Mar;42(4):501-8 [16406574.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Ann Oncol. 2002 Mar;13(3):460-9 [11996479.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2126-31 [7931483.001]
  • [Cites] Ann Oncol. 2001 Mar;12(3):311-9 [11332141.001]
  • [Cites] J Natl Cancer Inst. 1996 Mar 6;88(5):270-8 [8614005.001]
  • [Cites] Pediatr Blood Cancer. 2006 Sep;47(3):232-4 [16830319.001]
  • [Cites] Surg Gynecol Obstet. 1992 Dec;175(6):507-14 [1333095.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1187-90 [2162911.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):349-60 [2544249.001]
  • [Cites] Ann Surg. 2001 Jul;234(1):116-21 [11420491.001]
  • [Cites] Lancet. 2004 Oct 2-8;364(9441):1229-35 [15464183.001]
  • [Cites] Med Pediatr Oncol. 1992;20(4):360-1 [1318997.001]
  • [Cites] Eur J Cancer. 1996 May;32A(5):826-30 [9081361.001]
  • [Cites] Klin Padiatr. 2004 May-Jun;216(3):132-40 [15175957.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1181-7 [9820177.001]
  • [Cites] Urol Clin North Am. 2000 Aug;27(3):435-42 [10985143.001]
  • [Cites] Med Pediatr Oncol. 2002 Jul;39(1):18-24 [12116074.001]
  • [Cites] Cancer Res. 2000 Aug 1;60(15):4030-2 [10945603.001]
  • [Cites] Expert Rev Anticancer Ther. 2001 Dec;1(4):555-64 [12113088.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):339-47 [2822073.001]
  • [Cites] Eur J Pediatr Surg. 1998 Apr;8(2):83-6 [9617606.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1989 Nov;1(2):75-9 [2486484.001]
  • [Cites] Arch Pathol Lab Med. 2003 Oct;127(10):1280-9 [14521468.001]
  • [Cites] Cancer. 1991 Dec 1;68(11):2345-53 [1657352.001]
  • [Cites] J Clin Oncol. 1985 Apr;3(4):513-20 [2984344.001]
  • [Cites] J Urol. 2006 Jul;176(1):279-83; discussion 283-4 [16753419.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3744-51 [9850017.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1632-6 [6245781.001]
  • [Cites] J Urol. 2003 Sep;170(3):939-42; discussion 943-4 [12913746.001]
  • [Cites] Urology. 1996 Jun;47(6):787-91 [8677564.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):600-4 [7812929.001]
  • [Cites] Arch Dis Child. 1987 May;62(5):461-4 [3606177.001]
  • [Cites] Radiology. 1999 Apr;211(1):249-56 [10189480.001]
  • [Cites] Curr Opin Urol. 2005 Jul;15(4):273-6 [15928519.001]
  • [Cites] AJR Am J Roentgenol. 1999 Mar;172(3):759-63 [10063876.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1478-81 [8393095.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Jun;2(6):298-304; quiz 1 p following 324 [16264987.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):819-29 [12123328.001]
  • [Cites] Semin Pediatr Surg. 2006 Feb;15(1):3-9 [16458840.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1996;8(4):250-3 [8871004.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):37-44 [15162142.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1991-8 [12673729.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):292-7 [10024113.001]
  • [Cites] Eur J Pediatr. 1993 Mar;152(3):197-200 [8383053.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1616-25 [10193955.001]
  • [Cites] J Pediatr Surg. 1996 Aug;31(8):1020-5 [8863224.001]
  • [Cites] Am J Obstet Gynecol. 2002 Oct;187(4):1070-80 [12389007.001]
  • [Cites] Cancer. 1981 May 1;47(9):2302-11 [6164480.001]
  • [Cites] Lancet. 2004 Oct 23-29;364(9444):1468-70 [15500874.001]
  • [Cites] J Pediatr Surg. 1998 Feb;33(2):165-70 [9498380.001]
  • [Cites] Am J Med Genet. 1998 Oct 2;79(4):268-73 [9781906.001]
  • [Cites] J Clin Oncol. 2004 Dec 15;22(24):4979-90 [15576413.001]
  • [Cites] J Urol. 2005 Oct;174(4 Pt 1):1172-3 [16145362.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9138-45 [16172460.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2631-5 [9215834.001]
  • [Cites] Hematol Oncol Clin North Am. 1995 Dec;9(6):1317-27 [8591968.001]
  • [Cites] Surg Clin North Am. 2006 Apr;86(2):469-87, xi [16580935.001]
  • [Cites] Med Pediatr Oncol. 1997 Oct;29(4):239-44 [9251727.001]
  • [Cites] BJU Int. 2006 Jul;98(1):155-9 [16831161.001]
  • [Cites] Cancer. 1976 Aug;38(2):633-46 [184912.001]
  • [Cites] Med Pediatr Oncol. 1993;21(3):172-81 [7680412.001]
  • [Cites] Med Pediatr Oncol. 1996 Feb;26(2):145-6 [8531855.001]
  • [Cites] Cancer. 1976 Aug;38(2):647-54 [184913.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2331-3 [8162576.001]
  • [Cites] Pediatr Blood Cancer. 2006 Feb;46(2):149-58 [16369924.001]
  • [Cites] J Urol. 2005 Nov;174(5):1972-5 [16217371.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):672-8 [11058888.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7312-21 [16129848.001]
  • [Cites] J Urol. 2005 Jun;173(6):2147 [15879875.001]
  • [Cites] Radiology. 1982 Mar;142(3):643-7 [6278535.001]
  • [Cites] Eur J Pediatr Surg. 1994 Feb;4(1):16-20 [8199126.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):912-5 [1322458.001]
  • [Cites] J Urol. 2004 Sep;172(3):1066-9; discussion 1069-70 [15311039.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1014-23 [8388918.001]
  • [Cites] Med Pediatr Oncol. 1990;18(6):441-6 [2172754.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1092-8 [12402147.001]
  • [Cites] Urol Clin North Am. 2000 Aug;27(3):443-54 [10985144.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17 ):3269-75 [12947062.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1851-9 [7636528.001]
  • [Cites] Semin Urol Oncol. 1999 Feb;17(1):28-32 [10073403.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2885-90 [15254057.001]
  • (PMID = 18026723.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 119
  •  go-up   go-down


8. Schenk JP, Günther P, Schrader C, Ley S, Furtwängler R, Leuschner I, Edelhäuser M, Graf N, Tröger J: [Childhood kidney tumors -- the relevance of imaging]. Radiologe; 2005 Dec;45(12):1112-23
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Childhood kidney tumors -- the relevance of imaging].
  • Kidney tumors represent 6.2% of malignant tumors in children.
  • History, clinical course and radiological findings are necessary elements in the differential diagnosis of the different renal tumors.
  • In the case of nephroblastoma, chemotherapy is based solely on the radiological diagnosis without prior histology.
  • In therapy-optimizing studies of the Society of Pediatric Oncology and Hematology, preoperative chemotherapy is performed.
  • Therapy monitoring is performed in the course of and after preoperative chemotherapy to verify tumor response.
  • Radiological staging plays a significant role in deciding on further treatment and in operative planning.
  • In summary, diagnostic imaging in renal tumors in children plays a role in differential diagnosis, staging, monitoring of therapy, and surgical planning.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Magnetic Resonance Imaging. Tomography, X-Ray Computed. Wilms Tumor / diagnosis
  • [MeSH-minor] Abnormalities, Multiple / diagnosis. Adolescent. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Infant, Newborn. Kidney / pathology. Kidney Diseases / diagnosis. Male. Neoplasm Staging. Ultrasonography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2001 Jan;192(1):63-8; quiz 146 [11192924.001]
  • [Cites] AJR Am J Roentgenol. 1997 Feb;168(2):447-51 [9016225.001]
  • [Cites] Int J Urol. 2004 Jan;11(1):50-2 [14678186.001]
  • [Cites] Pediatr Radiol. 1994;24(2):85-7 [8078728.001]
  • [Cites] Pediatr Radiol. 2004 Aug;34(8):660-4 [15103425.001]
  • [Cites] Urol Radiol. 1992;14 (4):241-51 [1335188.001]
  • [Cites] Cancer. 1978 Oct;42(4):1922-8 [213188.001]
  • [Cites] J Urol. 1998 Jul;160(1):141-5 [9628635.001]
  • [Cites] Urologe A. 2003 Mar;42(3):W391-407; quiz W408-9 [12723542.001]
  • [Cites] Langenbecks Arch Chir Suppl Kongressbd. 1996;113:1078-83 [9101785.001]
  • [Cites] Am J Surg Pathol. 1989 Jun;13(6):439-58 [2543225.001]
  • [Cites] Klin Padiatr. 2004 May-Jun;216(3):132-40 [15175957.001]
  • [Cites] Hum Pathol. 1983 Jun;14(6):481-92 [6303938.001]
  • [Cites] Radiographics. 2000 Nov-Dec;20(6):1585-603 [11112813.001]
  • [Cites] Urologe A. 2004 Apr;43(4):421-8 [15042291.001]
  • [Cites] Med Pediatr Oncol. 2000 Mar;34(3):183-90 [10696124.001]
  • [Cites] Radiologe. 2001 May;41(5):418-26 [11405103.001]
  • [Cites] Pediatr Radiol. 1995 Nov;25 Suppl 1:S73-5 [8577561.001]
  • [Cites] Radiology. 1991 Sep;180(3):715-7 [1871282.001]
  • [Cites] J Pediatr. 1987 Jul;111(1):64-70 [3037055.001]
  • [Cites] Rofo. 2004 Jul;176(7):965-71 [15237338.001]
  • [Cites] Australas Radiol. 1999 Nov;43(4):532-4 [10901975.001]
  • [Cites] J Urol. 2003 Sep;170(3):939-42; discussion 943-4 [12913746.001]
  • [Cites] AJR Am J Roentgenol. 1980 Aug;135(2):381-4 [6250384.001]
  • [Cites] Radiographics. 1998 Jul-Aug;18(4):947-68 [9672980.001]
  • [Cites] Eur J Pediatr Surg. 2004 Oct;14(5):316-21 [15543480.001]
  • [Cites] Chirurg. 1996 Jun;67(6):584-92 [8767086.001]
  • [Cites] Rofo. 2004 Oct;176(10):1447-52 [15383976.001]
  • [Cites] Br J Cancer. 1980 Jun;41(6):875-9 [6252920.001]
  • [Cites] Histopathology. 1998 Apr;32(4):293-309 [9602325.001]
  • [Cites] Pediatr Radiol. 1999 Feb;29(2):100-3 [9933328.001]
  • [Cites] J Pediatr Surg. 2000 May;35(5):677-9 [10813321.001]
  • [Cites] J Pediatr Surg. 1998 Feb;33(2):165-70 [9498380.001]
  • [Cites] Rofo. 2005 Oct;177(10):1373-9 [16170706.001]
  • [Cites] Radiology. 1995 Apr;195(1):83-5 [7892499.001]
  • [Cites] Radiographics. 2000 Jan-Feb;20(1):215-43 [10682782.001]
  • [Cites] J Pediatr Surg. 2005 Feb;40(2):364-70 [15750930.001]
  • [Cites] Urologe A. 2002 Nov;41(6):577-82 [12524945.001]
  • [Cites] Pediatr Radiol. 2002 Nov;32(11):829-31 [12389112.001]
  • [Cites] Pediatr Radiol. 2003 Feb;33(2):123-8 [12557069.001]
  • [Cites] Radiology. 1993 Aug;188(2):517-21 [8392214.001]
  • [Cites] Pediatr Pathol Lab Med. 1995 Sep-Oct;15(5):745-62 [8597860.001]
  • [Cites] Radiology. 1988 Jan;166(1 Pt 1):153-6 [2827229.001]
  • [Cites] Urologe A. 2005 Feb;44(2):155-61 [15672236.001]
  • [Cites] Vestn Rentgenol Radiol. 2001 Nov-Dec;(6):29-43 [11858031.001]
  • [Cites] J Pediatr Surg. 1995 Jun;30(6):856-9 [7666322.001]
  • [Cites] Radiol Clin North Am. 1997 Nov;35(6):1391-413 [9374996.001]
  • [Cites] Pediatr Radiol. 1998 Jun;28(6):435-43 [9634458.001]
  • [Cites] Perspect Pediatr Pathol. 1976;3:185-223 [184429.001]
  • [Cites] Br J Urol. 1996 Nov;78(5):772-6 [8976777.001]
  • [Cites] J Pediatr. 1998 Mar;132(3 Pt 1):377-9 [9544882.001]
  • [Cites] J Pediatr Surg. 1991 Jan;26(1):64-7 [1848614.001]
  • (PMID = 16151729.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Wiesbauer P: [Nephrogenic tumors]. Radiologe; 2008 Oct;48(10):932-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nephroblastomas are the most common malignant renal tumors in childhood.
  • According to the guidelines of the SIOP (Société Internationale d'Oncologie Pédiatrique) and GPOH (Gesellschaft für Pädiatrische Onkologie und Hämatologie) pre-operative chemotherapy can be started without histological confirmation and thus initial imaging studies, in particular ultrasound, play an outstanding role for diagnostic purposes.
  • [MeSH-major] Kidney Neoplasms. Wilms Tumor
  • [MeSH-minor] Adult. Age Factors. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Incidence. Kidney / pathology. Liver Neoplasms / secondary. Magnetic Resonance Imaging. Male. Neoplasm Staging. Practice Guidelines as Topic. Randomized Controlled Trials as Topic. Tomography, X-Ray Computed. Ultrasonography

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Radiol. 2006 Jul;36(7):714-7 [16770676.001]
  • [Cites] AJR Am J Roentgenol. 1997 Feb;168(2):447-51 [9016225.001]
  • [Cites] Pediatr Nephrol. 1992 Jul;6(4):365-82 [1323320.001]
  • [Cites] Pediatr Radiol. 2004 Aug;34(8):660-4 [15103425.001]
  • [Cites] Radiographics. 2000 Nov-Dec;20(6):1585-603 [11112813.001]
  • [Cites] Pediatr Radiol. 2001 Oct;31(10):732-6 [11685444.001]
  • [Cites] J Pediatr Surg. 2004 Apr;39(4):522-5 [15065020.001]
  • [Cites] Pediatr Radiol. 2000 Aug;30(8):533-7; discussion 537-9 [10993537.001]
  • [Cites] Eur Radiol. 2003 Dec;13 Suppl 4:L116-29 [15018176.001]
  • [Cites] Cancer Imaging. 2007 Mar 05;7:41-51 [17339140.001]
  • [Cites] Pediatr Radiol. 1997 Mar;27(3):285 [9126596.001]
  • [Cites] Pediatr Radiol. 2003 Sep;33(9):594-7 [12856167.001]
  • [Cites] Pediatr Radiol. 1994;24(3):213-5 [7936803.001]
  • [Cites] Acta Radiol. 1995 May;36(3):254-60 [7742117.001]
  • [Cites] Eur J Pediatr Surg. 2001 Apr;11(2):92-8 [11371043.001]
  • [Cites] Pediatr Radiol. 2004 Feb;34(2):152-5 [14530886.001]
  • [Cites] Br J Cancer. 1980 Jun;41(6):875-9 [6252920.001]
  • [Cites] Radiographics. 1995 May;15(3):653-69 [7624570.001]
  • [Cites] Urol Clin North Am. 2000 Aug;27(3):463-9, ix [10985146.001]
  • [Cites] Eur J Pediatr Surg. 1996 Jun;6(3):186-8 [8817218.001]
  • [Cites] Pediatr Radiol. 2003 Feb;33(2):123-8 [12557069.001]
  • [Cites] Urologe A. 2005 Feb;44(2):155-61 [15672236.001]
  • [Cites] Clin Radiol. 1999 May;54(5):321-7 [10362240.001]
  • [Cites] Radiol Clin North Am. 1997 Nov;35(6):1391-413 [9374996.001]
  • [Cites] Pediatr Radiol. 1998 Jun;28(6):435-43 [9634458.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2002 May;10(2):275-302 [12424947.001]
  • (PMID = 18854965.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Masucci GV, Månsson-Brahme E, Ragnarsson-Olding B, Nilsson B, Wagenius G, Hansson J: Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma. Melanoma Res; 2006 Aug;16(4):357-63
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous clinical trials suggested that temozolomide in sequence with low-dose recombinant human interleukin-2 might be an efficacious and relatively non-toxic chemo-immunotherapeutic treatment, which may synergistically eliminate tumours.
  • The primary objective was to determine the safety and tolerance of temozolomide administered orally 200 mg/m days 1-5, in sequential combination with subcutaneous injections of 4.5x10 IU recombinant human interleukin-2 on days 8-11, 15-18 and 22-25 in patients with measurable, progressive metastatic malignant melanoma without radiological signs of central nervous system metastases.
  • The secondary objectives were to determine tumour response and time to progression.
  • Three patients suspended the treatment because of WHO grade 3 side effects already during the first 3 days of the first course of temozolomide.
  • Seven patients showed no tumour progression during the first four treatment cycles.
  • Two patients had complete responses, three partial responses and two stable disease at the end of the four cycles defined by the protocol and they continued the treatment until signs of relapse or a maximum of 21 courses.
  • Thrombocytopenia was significantly more pronounced in patients with objective response and stable disease than in non-responders to therapy.
  • The median time to progression for all patients was 3.1 months and for responding and stable disease patients was 15 months.
  • Five of 23 treated patients (22%) developed brain metastases during follow-up.
  • Temozolomide in combination with recombinant human interleukin-2 is a well-tolerated regimen for outpatient treatment and the bio-chemotherapy combination induced durable clinical responses.
  • Thrombocytopenia might be a positive predictive factor for response to therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Melanoma / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Female. Humans. Immunotherapy. Injections, Subcutaneous. Interleukin-2 / administration & dosage. Lymphatic Metastasis / immunology. Lymphatic Metastasis / pathology. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Skin Neoplasms / drug therapy. Skin Neoplasms / immunology. Skin Neoplasms / pathology. Survival Rate

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16845332.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interleukin-2; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


11. Schenk JP, Graf N, Günther P, Ley S, Göppl M, Kulozik A, Rohrschneider WK, Tröger J: Role of MRI in the management of patients with nephroblastoma. Eur Radiol; 2008 Apr;18(4):683-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging (MRI) presents the main diagnostic tool for differentiation and staging of renal tumors in childhood.
  • Nephroblastoma is the most common malignant tumor in children.
  • Radiological findings play an important role in therapy study trials of SIOP (International Society of Pediatric Oncology), especially for indicating preoperative chemotherapy.
  • In the past few years MRI has gained great importance in imaging of nephroblastoma and has replaced computed tomography (CT).
  • The aim of this review is to present the diagnostic possibilities of MRI in relation to the requirements of therapy studies.
  • For nephroblastoma, MRI provides important information about tumor extent and distant metastasis.
  • A special focus of MRI in distant staging is venous extent of the tumor into the inferior vena cava.
  • In addition, MRI has an important role in monitoring chemotherapy and in preoperative planning by volume rendering and three-dimensional postprocessing.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Wilms Tumor / diagnosis
  • [MeSH-minor] Child. Contrast Media. Humans. Image Interpretation, Computer-Assisted. Imaging, Three-Dimensional. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2001 Jan;192(1):63-8; quiz 146 [11192924.001]
  • [Cites] Rofo. 2006 Jan;178(1):38-45 [16392056.001]
  • [Cites] Pediatr Radiol. 1994;24(2):85-7 [8078728.001]
  • [Cites] Pediatr Radiol. 2005 Aug;35(8):766-73 [15864576.001]
  • [Cites] Radiographics. 2004 Sep-Oct;24(5):1317-30 [15371611.001]
  • [Cites] Pediatr Radiol. 2004 Aug;34(8):660-4 [15103425.001]
  • [Cites] Radiologe. 2005 Dec;45(12 ):1112-23 [16151729.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jul;177(1):229-36 [11418435.001]
  • [Cites] Langenbecks Arch Chir Suppl Kongressbd. 1996;113:1078-83 [9101785.001]
  • [Cites] Klin Padiatr. 2004 May-Jun;216(3):132-40 [15175957.001]
  • [Cites] Med Pediatr Oncol. 2000 Mar;34(3):183-90 [10696124.001]
  • [Cites] Radiologe. 2001 May;41(5):418-26 [11405103.001]
  • [Cites] J Urol. 2003 Sep;170(3):939-42; discussion 943-4 [12913746.001]
  • [Cites] Pediatr Pathol. 1990;10(1-2):1-36 [2156243.001]
  • [Cites] Radiographics. 1998 Jul-Aug;18(4):947-68 [9672980.001]
  • [Cites] Eur J Pediatr Surg. 2004 Oct;14(5):316-21 [15543480.001]
  • [Cites] Rofo. 2004 Oct;176(10):1447-52 [15383976.001]
  • [Cites] J Pediatr Surg. 1998 Feb;33(2):165-70 [9498380.001]
  • [Cites] Rofo. 2005 Oct;177(10):1373-9 [16170706.001]
  • [Cites] Pediatr Radiol. 2006 Oct;36(10):1075-81 [16896692.001]
  • [Cites] J Pediatr Surg. 2005 Feb;40(2):364-70 [15750930.001]
  • [Cites] Radiology. 1993 Aug;188(2):517-21 [8392214.001]
  • [Cites] Rofo. 2005 Jun;177(6):800-4 [15902628.001]
  • [Cites] Vestn Rentgenol Radiol. 2001 Nov-Dec;(6):29-43 [11858031.001]
  • [Cites] Pediatr Radiol. 1998 Jun;28(6):435-43 [9634458.001]
  • [Cites] Br J Urol. 1996 Nov;78(5):772-6 [8976777.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2002 May;10(2):275-302 [12424947.001]
  • [Cites] Urol Clin North Am. 2000 Aug;27(3):443-54 [10985144.001]
  • [Cites] J Pediatr Surg. 1991 Jan;26(1):64-7 [1848614.001]
  • (PMID = 18193429.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 30
  •  go-up   go-down


12. Suita S, Kinoshita Y, Tajiri T, Hara T, Tsuneyoshi M, Mizote H, Inada H, Takamatsu H, Kawano Y, Inomata Y, Nagasaki A, Ono Y, Handa N, Okamura J, Ishii E, Kawakami K, Committee for pediatric solid malignant tumors in the Kyushu area: Clinical characteristics and outcome of Wilms tumors with a favorable histology in Japan: a report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan. J Pediatr Surg; 2006 Sep;41(9):1501-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcome of Wilms tumors with a favorable histology in Japan: a report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan.
  • BACKGROUND/PURPOSE: Since 1996, the standard treatment of Wilms tumors in Japan has been based on the regimen of the Japanese Wilms Tumor Study.
  • This study aims to assess the clinical characteristics of patients with Wilms tumor with a favorable histology from a retrospective standpoint in the Kyushu area in Japan and, furthermore, to analyze the historical changes of clinical features and outcome from the 1980s to the 1990s.
  • All stage V cases in group B undewent a bilateral tumor biopsy instead of a radical nephrectomy as the initial operation.
  • The present study suggested that in the early-stage cases, an initially complete resection followed by standard postoperative chemotherapy substantially improved the outcome of the patients in group B.
  • In the stage V cases, the performance of renal salvage surgery may have positively contributed to the improvement in the outcome in group B.
  • In the future, an improved efficacy of the treatments for Wilms tumors based on the standard protocol established by the Japanese Wilms Tumor Study in 1996 is expected in Japan.
  • [MeSH-major] Kidney Neoplasms / mortality. Wilms Tumor / mortality
  • [MeSH-minor] Child, Preschool. Female. Humans. Infant. Infant, Newborn. Japan. Male. Neoplasm Staging. Nephrectomy. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952581.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Koschmieder S, Fauth F, Kriener S, Hoelzer D, Seipelt G: Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma. Leuk Lymphoma; 2002 Mar;43(3):645-7
Genetic Alliance. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma.
  • Malignant lymphomas have been reported previously to coincide with adenocarcinomas of the stomach and, rarely, the kidney, breast, colon, liver, or lung.
  • Here, we describe the first case to our knowledge of a malignant lymphoma and an extensive disease small cell cancer of the lung.
  • Further staging revealed a dense infiltration of the bone marrow by both a small cell lung cancer and a malignant lymphoma.
  • Both tumors responded well to chemotherapy.
  • This unique case report demonstrates that the simultaneous occurrence of small cell lung cancers and malignant lymphomas is extremely rare and may effectively be treated with chemotherapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow / pathology. Humans. Liver / pathology. Male. Middle Aged. Neoplasm Invasiveness. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12002773.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


14. Stephenson AJ: Current treatment options for clinical stage I seminoma. World J Urol; 2009 Aug;27(4):427-32
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current treatment options for clinical stage I seminoma.
  • Adjuvant radiotherapy, surveillance, and single-agent carboplatin chemotherapy are all accepted treatment options for clinical stage (CS) I seminoma with cure rates approaching 100%.
  • Low-dose (25-35 Gy) adjuvant radiotherapy to the retroperitoneum and ipsilateral pelvis has been the mainstay of treatment for decades and is associated with excellent long-term survival and acceptable short-term toxicity.
  • The use of lower radiation doses (20 Gy) and the omission of pelvic radiation have been investigated to reduce toxicity.
  • However, the risk of late toxicity (specifically cardiovascular disease and secondary malignant neoplasms) resulting from radiation exposure have diminished the appeal of this approach, particularly given the fact that 80-85% of patients are cured by orchiectomy.
  • The appeal of surveillance is the avoidance of treatment-related morbidity in 80-85% of patients and the successful salvage of relapses with 30-35 Gy radiotherapy in most cases.
  • However, given the prolonged time course to relapse in CS I seminoma on surveillance, long-term follow-up with frequent abdominal-pelvic imaging is required.
  • However, concerns about the risk of inadequate therapy and late toxicity limit the acceptance of this approach until long-term results are available.
  • With potential of avoiding treatment-related toxicity without compromising curability and given the overall low risk of occult metastasis in clinical stage I seminoma, surveillance is the recommended treatment option.
  • [MeSH-major] Seminoma / drug therapy. Seminoma / radiotherapy. Testicular Neoplasms / drug therapy. Testicular Neoplasms / radiotherapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Combined Modality Therapy. Humans. Male. Neoplasm Staging. Population Surveillance. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):640-7 [14726503.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1310-5 [17416851.001]
  • [Cites] Lancet. 2005 Jul 23-29;366(9482):293-300 [16039331.001]
  • [Cites] N Engl J Med. 2007 Nov 29;357(22):2277-84 [18046031.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Apr 30;29(1):3-8 [8175442.001]
  • [Cites] Urology. 2002 Aug;60(2):324-8 [12137835.001]
  • [Cites] J Urol. 2005 Mar;173(3):824-9 [15711278.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):101-4 [11134201.001]
  • [Cites] Br J Cancer. 2004 Jun 14;90(12):2305-11 [15150576.001]
  • [Cites] APMIS. 2003 Jan;111(1):76-83; discussion 83-5 [12752240.001]
  • [Cites] Eur J Cancer. 1993;29A(14):1931-4 [8280484.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8717-23 [16260698.001]
  • [Cites] Ann Oncol. 2003 Jun;14(6):867-72 [12796024.001]
  • [Cites] Br J Cancer. 1992 May;65(5):775-8 [1586607.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2255-62 [7666083.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5524-9 [18936477.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Mar 1;61(3):736-40 [15708251.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1146 [10561173.001]
  • [Cites] Urology. 2000 Jan;55(1):102-6 [10654903.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1200-8 [15718317.001]
  • [Cites] Eur J Cancer. 2002 Jan;38(1):11-6 [11750834.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):383-8 [2921142.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [16174857.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4448-52 [12431967.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4370-8 [17906202.001]
  • [Cites] Can J Urol. 2002 Oct;9(5):1637-40 [12431325.001]
  • (PMID = 19370354.001).
  • [ISSN] 1433-8726
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


15. Amel L, Leila BF, Lamia K, Olfa G, Abdelfattah Z, Mondher G, Faouzi M, Chakib K, Abdelatif N, Amor G, Slim BA: [Histologic and prognostic study of nephroblastoma in central Tunisia]. Ann Urol (Paris); 2003 Aug;37(4):164-9
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Etude anatomoclinique et pronostique des néphroblastomes dans le centre tunisien.
  • Nephroblastoma is a common malignant tumour in childhood that benefited from therapeutic progress.
  • We report and compare clinical features, therapeutic results and prognostic factors with those reported in the literature.
  • Pre-operative chemotherapy was done in 32 cases and the objective response rate was 58%.
  • Prognosis of nephroblastoma has been improved with chemotherapy and the pluridisciplinar treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Nephrectomy. Wilms Tumor / drug therapy. Wilms Tumor / pathology
  • [MeSH-minor] Adolescent. Age of Onset. Child. Child, Preschool. Female. Humans. Infant. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Tunisia

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12951705.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


16. Cozzi DA, Schiavetti A, Morini F, Castello MA, Cozzi F: Nephron-sparing surgery for unilateral primary renal tumor in children. J Pediatr Surg; 2001 Feb;36(2):362-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nephron-sparing surgery for unilateral primary renal tumor in children.
  • PURPOSE: Definition of the role of nephron-sparing surgery (NSS) in the treatment of children with primary unilateral renal tumor (URT).
  • Criteria for selection of patients eligible for NSS were at least 50% of affected kidney preservable and stage I at surgery (frozen section biopsies from regional lymph nodes, perirenal fat, and surrounding renal parenchyma).
  • Preoperative 2-drug chemotherapy was given to all patients more than 6 months of age.
  • Between 1992 and 1995, 3-drug chemotherapy was used after NSS.
  • Thereafter, following NSS, 2-drug chemotherapy was given if no microscopic residual disease was found on final histologic examination.
  • Seven children had standard histology nephroblastoma, 1 highly differentiated epithelial type nephroblastoma, 1 oncocytoma, and 1 cystic nephroma.
  • All children are alive and disease free with good functioning of the affected kidney after NSS, at a mean follow-up of 40.7 months (range, 2 to 100 months).
  • CONCLUSION: NSS should be considered in selected children with URT, especially in patients with increased risk for metachronous tumor or renal disease, and in patients with benign or low-grade malignant URT.
  • [MeSH-major] Kidney Neoplasms / surgery. Nephrectomy / methods
  • [MeSH-minor] Child. Child, Preschool. Eligibility Determination. Female. Humans. Infant. Infant, Newborn. Life Expectancy. Male. Neoplasm Staging. Postoperative Complications. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11172435.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Basta-Jovanović G, Radonjic V, Stolic I, Nenadovic M, Brasanac D, Jovanovic D, Radojevic-Skodric S: Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor. Ren Fail; 2005;27(1):13-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor.
  • The rate of apoptosis varies in malignant tumors, and it can be involved in diminishing tumor size.
  • In human renal diseases, such as the experimental model of acute renal failure, and many tumors, including Wilms' tumor, the expression of antiapoptotic members of Bcl-2 family is increased, while the expression of proapoptotic members is low.
  • AIM: The aim of our study was to investigate Bcl-X(S/L) protein expression in Wilms' tumor, to compare it with the expression in normal renal tissue, as well as to see if there is a correlation between Bcl-X(S/L) expression in Wilms' tumor with tumor stage, histological type, prognostic group, or response to preoperative chemotherapy.
  • MATERIALS AND METHODS: Twenty-eight cases of Wilms' tumor (two cases with metastasis) and two samples of normal kidney tissue were studied using streptavidin-biotin-complex technique.
  • RESULTS: The expression of Bcl-X(S/L) was observed in the majority of cases (60.7%), more often in the blastemal than in the epithelial component of Wilms' tumor: 60.7% and 28.6%, respectively (p=0.02).
  • There was a statistically significant inverse relationship between Bcl-X(S/L) expression and tumor stage (p=0.015).
  • Expression of Bcl-X(S/L) was detected in various histological types of Wilms' tumor, but there was no statistically significant association (p=0.82) except in cases with diffuse anaplasia (p=0.012), which were always negative.
  • No Bcl-X(S/L) immunostaining was observed in two cases of metastasis or in one case of bilateral Wilms' tumor.
  • CONCLUSION: Our results suggest that the expression of Bcl-X(S/L) protein is associated with prognostic group, tumor stage, and presence of anaplasia.
  • [MeSH-major] Kidney / pathology. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Wilms Tumor / metabolism
  • [MeSH-minor] Anaplasia. Antineoplastic Agents / therapeutic use. Apoptosis. Child. Child, Preschool. Female. Humans. Infant. Male. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. bcl-X Protein

  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15717629.001).
  • [ISSN] 0886-022X
  • [Journal-full-title] Renal failure
  • [ISO-abbreviation] Ren Fail
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-X Protein
  •  go-up   go-down


18. Eilber FC, Eilber KS, Eilber FR: Retroperitoneal sarcomas. Curr Treat Options Oncol; 2000 Aug;1(3):274-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging of the abdomen and pelvis by computed tomography (CT) provides both an imaging modality and a method by which to obtain tissue for diagnosis.
  • Because a histologic diagnosis is essential in treatment planning, adequate tissue can usually be obtained by a CT-guided core biopsy.
  • If the diagnosis is sarcoma, additional tests necessary for staging include plain chest radiography and evaluation of the liver by either CT scan or magnetic resonance imaging (MRI).
  • The treatment options for primary retroperitoneal sarcomas include chemotherapy, radiation therapy, surgery, or a combination of these modalities; therefore, a multidisciplinary group best manages treatment planning.
  • Primary radiation therapy for cure is seldom effective for retroperitoneal sarcomas but can provide palliation in select cases.
  • Systemic chemotherapy for chemosensitive lesions, such as poorly differentiated liposarcoma, malignant fibrous histiocytoma (MFH), synovial cell sarcoma, and primitive neuroectodermal tumors (PNET), can be useful when used in a neoadjuvant manner.
  • Consequently, surgical resection continues to be the mainstay of treatment for retroperitoneal sarcomas and requires en bloc resection of the primary tumor.
  • Frequently this includes adjacent organs such as colon, small bowel, kidney, adrenal, and pancreas.
  • Postoperative adjuvant therapy with chemotherapy or radiation has not been proven to be of any additional benefit.
  • Overall treatment results are predominantly influenced by tumor stage, grade, size, and margins of surgical resection.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy / methods. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] Surg Oncol. 1998 Jul-Aug;7(1-2):77-81 [10421510.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1077-83 [10091791.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):328-34 [1998475.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):170-8 [2104923.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] Ann Intern Med. 1982 Feb;96(2):133-9 [7059060.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] Ann Surg. 1991 Jul;214(1):2-10 [2064467.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] Adv Surg. 1997;31:395-420 [9408503.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):912-6 [1913104.001]
  • [Cites] Oncology (Williston Park). 1996 Dec;10(12):1867-72; discussion 1872-4 [8985970.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):402-10 [8457152.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):526-33 [9344318.001]
  • (PMID = 12057171.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


19. van den Hoek J, de Krijger R, van de Ven K, Lequin M, van den Heuvel-Eibrink MM: Cystic nephroma, cystic partially differentiated nephroblastoma and cystic Wilms' tumor in children: a spectrum with therapeutic dilemmas. Urol Int; 2009;82(1):65-70
MedlinePlus Health Information. consumer health - Wilms Tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic nephroma, cystic partially differentiated nephroblastoma and cystic Wilms' tumor in children: a spectrum with therapeutic dilemmas.
  • BACKGROUND: Cystic renal tumors are a diagnostic and therapeutic challenge.
  • Cystic nephroma (CN), cystic partially differentiated nephroblastoma (CPDN) and cystic Wilms' tumor (CWT) are a spectrum with CN at the benign end, CWT at the malignant end and CPDN in the intermediate position.
  • International Society of Pediatric Oncology (SIOP) protocols for Wilms' tumor (WT) advocate preoperative chemotherapy, which may be unnecessary and potentially harmful in CN and in stage 1 CPDN.
  • There are difficulties in differentiating the three types using imaging techniques.
  • Therefore, controversies exist regarding the optimal treatment.
  • METHODS: We describe 6 children, who each had a postoperative diagnosis of CN, CPDN or CWT, and we retrospectively evaluate the treatment strategies.
  • RESULTS: The three types cannot be differentiated using imaging techniques, although the presence of solid components in the tumor is indicative of WT.
  • CONCLUSIONS: Surgery as first-line therapy should be seriously considered in children who have a cystic renal tumor, but further collaborative studies are needed since the distinction line between CPDN and CWT is not always clear.
  • [MeSH-major] Kidney Diseases, Cystic / surgery. Kidney Neoplasms / surgery. Nephrectomy. Wilms Tumor / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Biopsy. Cell Differentiation. Chemotherapy, Adjuvant. Child, Preschool. Diagnosis, Differential. Disease Progression. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome. Ultrasonography

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19172100.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


20. Diagnosis and Therapy for Bone Metastasis of Malignant Tumors and Skeletal-Related Events Expert Group: [Diagnosis and treatment of bone metastasis of renal cancer: an expert consensus statement (2008 version)]. Zhonghua Zhong Liu Za Zhi; 2010 Apr;32(4):317-9
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of bone metastasis of renal cancer: an expert consensus statement (2008 version)].
  • [MeSH-major] Bone Neoplasms. Carcinoma, Renal Cell / therapy. Kidney Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzenesulfonates / therapeutic use. Humans. Interleukin-2 / analogs & derivatives. Interleukin-2 / therapeutic use. Neoplasm Staging. Niacinamide / analogs & derivatives. Pain / drug therapy. Pain / etiology. Phenylurea Compounds. Pyridines / therapeutic use. Recombinant Proteins / therapeutic use

  • Genetic Alliance. consumer health - Kidney cancer.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510090.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Interleukin-2; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Recombinant Proteins; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; M89N0Q7EQR / aldesleukin
  • [Investigator] Ma JH
  •  go-up   go-down






Advertisement